BioNTech CEO Sahin says a new vaccine will probably be needed by the middle of next year to fight off Covid variants. BioNTech (BNTX) Chief Executive Ugur Sahin says a new vaccine will ...

Moderna CEO Stéphane Bancel ... in the effectiveness of Pfizer-BioNTech versus omicron after just a few months creates new challenges." Dr. Paul Offit, a vaccine expert at the Children’s ...

Hong Kong will have another choice for a Covid-19 vaccine targeting the Omicron variant, with drug maker BioNTech offering to make its second-generation jabs available in the city as early as ...

Pfizer’s CEO Albert Bourla said ... People in Great Britain will be able to buy the latest Omicron-directed version of Pfizer/BioNTech’s COVID-19 vaccine from retail pharmacies, starting ...

BioNTech’s CEO said the company and partner Pfizer don’t need to halt their late-stage trial of a coronavirus vaccine due to side effects. The side effects that have cropped up in its study ...

The FDA's actions Monday related just to the vaccines manufactured by Moderna and Pfizer-BioNTech. Both of their vaccines ...

Yes, the Pfizer/BioNTech and Moderna Covid-19 vaccines have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA). Yes, that’s exciting news. Yes ...

BioNTech said that with Pfizer, it delivered their Omicron XBB.a.5-adapted COVID-19 vaccine. In 2023, the companies delivered more than 400 million COVID-19 vaccine doses worldwide, down from ...

BioNTech, which partnered with U.S. pharma giant Pfizer (PFE.N) , opens new tab for its COVID-19 vaccine, however, said it disagreed with the positions being taken by the NIH and intends to defend ...

The German pharma firm BioNTech on Monday said its vaccine sales were more than tripled ... placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong ...

Looking beyond immediate vaccine sales, BioNTech is shifting its strategic focus towards its oncology pipeline, which includes early to mid-stage trial readouts throughout the year. This shift is ...

Ugur Sahin, M.D., CEO and Co-Founder of BioNTech ... Key Post Period-End Events and 2024 Outlook Omicron XBB.1.5-adapted Monovalent COVID-19 Vaccine (COMIRNATY ®) BioNTech and Pfizer developed ...